An internal component of the actuators in a certain production batch may not meet the required mechanical strength. This could result, in the worst case scenario, in a sudden loss of the actuator's ability to hold the load, leading to rapid and uncontrolled downward movement of the lifting arm.
An internal component of the actuators in a certain production batch may not meet the required mechanical strength. This could result, in the worst case scenario, in a sudden loss of the actuator's ability to hold the load, leading to rapid and uncontrolled downward movement of the lifting arm.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact ARJOHUNTLEIGH POLSKA Sp. z.o.o. or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for ARJOHUNTLEIGH POLSKA Sp. z.o.o. recalls
Be the first to know. Free instant alerts to your inbox.
Arjo Tenor mobile passive patient lift, Model Numbers KHA1000 US and KHA1010 US. Reason: An internal component of the actuators in a certain production batch may not meet the required mechanical strength. This could result, in the worst case scenario, in a sudden loss of the actuator's ability to hold the load, leading to rapid and uncontrolled downward movement of the lifting arm.. Classification: Class II. Quantity: 119 units. Distribution: US Nationwide distribution.
Not sure what to do next? Our guide walks you through the process step by step.
Read: How to Get Refunds and ReplacementsGet instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Lack of Assurance of Sterility
Failed Stability Specifications
K.C. Pharmaceuticals recalled eight OTC eye drops sold nationwide under CVS Health, Walgreens and Kroger brands after sterility could not be verified. The recall covers all lots within expiry through Oct 31, 2026. Nonsterile eye drops can harbor bacteria and fungus, causing serious infections that may lead to vision loss. Stop using recalled products and return them for a full refund at the store.
Subpotent drug
Biocon Pharma Inc. recalled 88,008 bottles of Prazosin Hydrochloride capsules, 1 mg, 100-count bottles, nationwide in the United States. A cGMP deviation detected N-nitroso-prazosin impurity C above acceptable limits. Consumers and healthcare providers should stop using this product immediately and contact Appco Pharma LLC or a healthcare provider for guidance.
Biocon Pharma Inc. recalled 28,157 bottles of PRAZOSIN HYDROCHLORIDE capsules, distributed nationwide in the USA. The recall cites cGMP deviation due to detection of N-nitroso-prazosin impurity C above acceptable limits. Stop using the product immediately and contact Appco Pharma LLC or your healthcare provider for guidance.
Biocon Pharma Inc. recalled 58,896 bottles of Prazosin Hydrochloride Capsules, USP, 2 mg, 100-count bottle. The product was distributed nationwide in the USA and manufactured by Appco Pharma LLC. A cGMP deviation detected N-nitroso-prazosin impurity C above acceptable limits. Consumers and healthcare providers should stop using this product immediately and contact Appco Pharma LLC or their health‑